Progenitor Cell Therapy (PCT), a subsidiary of NeoStem, has signed an agreement to provide cell product development and manufacturing services for Adaptimmune’s clinical trials.
Adaptimmune will make use of PCT services in the development of its NYESO-1c259-T cell therapy targeting various oncology indications.
Adaptimmune chief executive officer James Noble said, “With our sights set on future pivotal trials for our T cell therapy products, we have invested significant effort towards establishing capabilities within Adaptimmune that support expansion of our clinical platform in terms of both scale and compliance with FDA requirements beyond phase I/II.”
PCT facility in Allendale, New Jersey, will provide transfer and qualification services essential for the NYESO-1c259-T cell therapy product manufacturing process following manufacturing of the product.
PCT president and chief scientific officer Robert Preti said, “Given our extensive experience with technology transfer, process qualification and GMP manufacturing, we feel PCT will be an asset to Adaptimmune as it develops its product for the U.S. commercial market.”
